Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813906 | 0.80 | TNKS (0.35) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL23599247 | 0.78 | PDPK1 (0.38) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL5313472 | 0.67 | PDPK1 (0.38) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL23498442 | 0.67 | SMN1; SMN2 (0.35) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL19024016 | 0.66 | KDM5B (0.32) | — | |
| SCHEMBL25393220 | 0.66 | HTT (0.40) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL23498507 | 0.65 | TNKS (0.50) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL21813942 | 0.65 | TNKS (0.36) | TNKSPARP1TNKS2KDM4EPDPK1 | |
| SCHEMBL18997486 | 0.65 | HTT (0.39) | TNKSPARP1TNKS2NPSR1KDM4E | |
| SCHEMBL10203314 | 0.64 | TNKS (0.38) | TNKSPARP1TNKS2NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | TNKS 2621/4885PARP1 1274/4885TNKS2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.